PLX Financial Facts
RESEARCH AND DEVELOPMENT EXPENSES, NET: -5.06MNET LOSS PER SHARE OF COMMON STOCK - BASIC AND DILUTED:: -0.07
See Full Income Statement
Total long term liabilities: 75.24M
Other: 5.84M
See Full Balance Sheet
Protalix Biotherapeutics, Inc. (PLX) Earnings
|
Expand Research on PLX
| Next EPS Date | 5/8/24 | EPS Growth Rate | N/A |
|---|---|---|---|
| Average EPS % Beat Rate | +11.7% | Revenue Growth Rate | N/A |
| Average % Move 1-Wk after EPS | -3.3% | Normal Earnings Time | Before Open |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 5/8/24 | Q124 | N/A | -$0.02 | N/A | N/A | $9.2M | N/A | N/A | N/A | ||
| 3/27/24 | Q423 | N/A | -$0.03 | N/A | N/A | $8.15M | N/A | N/A | N/A | ||
| 11/6/23 | Q323 | -$0.04 | -$0.04 | $0.00 | $10.34M | $10M | N/A |  | | Details | |
| 8/7/23 | Q223 | -$0.16 | N/A | N/A | $24.84M | $10.22M | N/A | | | Details | |
| 5/4/23 | Q123 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | ||
| 2/27/23 | Q422 | -$0.22 | -$0.15 | -$0.07 | $62.89M | $6.12M | N/A | | | Details | |
| 11/14/22 | Q322 | -$0.07 | -$0.15 | +$0.08 | $5.4M | $5.7M | N/A | | | Details | |
| 11/14/22 | Q322 | -$0.09 | -$0.15 | +$0.06 | $12.05M | $5.7M | N/A | | | Details |
